Press "Enter" to skip to content

Reversing Balding is Becoming Priority for Biotech

Due to both stress and the aftereffects of COVID 19, hairlines have receded faster than usual during the pandemic. Many people suffer increased hair shedding after a coronavirus infection, which begins two to three months after being ill and lasts for six to nine months. dNovo, a Silicon Valley Biotech startup, has created a potential answer to this issue. The business claims to have successfully converted ordinary cells, such as fat or blood cells, into human hair follicles.

dNovo can develop personalised hair stem cells from a few drops of blood, which can be utilised to grow new hair. The cells are thought to be impervious to any immune system response that would cause them to be rejected. DNovo, which was created by Ernesto Lujan, a Stanford University-trained scientist, had its first success in 2019 with a patent-pending technology that regenerates diverse types of human cells into hair stem cells.

Collecting cells, reprogramming them, generating new hair-producing cells, implanting those hair-producing cells into human scalps, and finally waiting one to three months for the hair to grow are the five steps in the procedure. Humans will have to wait years for technology to be ready. For the time being, its usefulness has only been demonstrated in mice.

DNovo isn’t the only firm experimenting with hair cells generated in the lab. Stemson Therapeutics, a Biotech startup, acquired $15 million in investment in July to develop a hair-loss cure utilising a unique cell regeneration method that uses the patient’s own cells to grow new hair follicles. Dr. Shinya Yamanaka, a Japanese researcher, discovered a formula for converting any type of human tissue into stem cells in 2006. Since their discovery, so-called iPSCs have been used to develop a variety of cutting-edge medicines.

Be First to Comment

Leave a Reply

Your email address will not be published.